Epstein-Barr virus (EBV). X. Incidence of EBV antibodies in patients with malignant tumors

Serum samples from 31 patients with various types of malignancies, 18 patients with different viral infections and 6 healthy subjects as controls, were tested by indirect immunofluorescence (IF) method for antibodies against viral capsid antigens (VCA) and the presence of active EBV infection. EBV antibodies anti-VCA were detected in 19 patients with tumors, in 8 patients with viral infections and in 2 healthy subjects. EBV active infection was found out in 9/19, 3/8 and 0/2 EBV anti-VCA positive patients with malignancies, different viral infections and healthy subjects respectively.     

Epstein-Barr virus (EBV). V. Incidence of EBV antibodies in patients with rheumatic diseases

Serum samples from 95 patients with rheumatoid arthritis, 24 patients with other various rheumatic diseases, 50 patients with diabetes mellitus, 34 patients with acute viral infections, 6 patients with infectious mononucleosis, 77 patients with lymphomas and leukemia and 110 blood donors and 24 healthy subjects as normal controls, respectively, were tested by indirect immunofluorescence (IF) reaction for the presence of specific antibodies against Epstein-Barr virus determined viral capsid antigen (anti-VCA) and Epstein-Barr active viral infection. The IF test carried out in acetone-fixed smears of EB-3 cell line revealed EB antibodies anti-VCA in 83.3% of infectious mononucleosis, 61.0% lymphomas and leukemia, 58.0% diabetic patients. The frequency of anti-VCA antibodies in rheumatic patients was 31.4%, and 3.6% and 25% in sera from blood donors and healthy subjects, respectively. Incidence of active EBV infection was 5.7% of rheumatic diseases, 17.7% of acute virus infections, 50.0% of infectious mononucleosis, and 31.1% of lymphomas and leukemia patients. Active EBV infection was not found out in blood donors (0/110) and healthy subjects (0/24) groups as control. Rheumatoid arthritis with or without rheumatoid factor patients had serological evidence of active EBV infection 6/26 and 4/26 respectively.     

Epstein-Barr virus (EBV). VI. Incidence of EBV antibodies in patients with malignant lymphoproliferative diseases

Serum samples from 52 patients with malignant lymphoproliferative diseases and 12 clinically healthy subjects were tested by indirect immunofluorescence (IF) reaction for the presence of specific EB antibodies anti-VCA and active EBV infection. The tests revealed EB antibodies anti-VCA in 32 patients with lymphoproliferative diseases and in 2 clinically healthy subjects and active EBV infection in 18/32 and in 0/2 EB anti-VCA positive patients and clinically healthy subjects, respectively.     

Investigations of the presence of serum antibodies to Epstein-Barr virus in patients with various tumors

Serum samples from 150 patients with various malignant or benign tumors and from 20 clinically healthy subjects were tested by indirect immunofluorescence (IF) reaction for the presence of specific antibodies to Epstein-Barr-virus-determined viral capsid antigen (EB VCA). The IF test-carried out in multitest-slide EB3 and Raji cell preparations-revealed antibodies to EB VCA in 102 of the patients with tumors and in 4 of the healthy persons.     

Epstein-Barr virus (EBV). IV. Studies on experimental inactivated vaccine against human EBV infection

It is well established that EBV-immunogen successfully invoke a strong neutralizing anti-EBV response in experimental animals. The authors report here the successful production of an EBV-immunogen prepared with whole disrupted productive cells of 2 MEBV cell line and with whole virus inactivated with ethylenimine (EI) which produce neutralizing anti-EBV response in experimental animals (calves, sheep, rabbits and SPF chickens).     

Epstein-Barr virus (EBV). VII. Established lymphoid cell line (IVPat-88) obtained from synovial fluid of a patient with aseptic arthritis

Attempts have been made to culture mononuclear cells from synovial fluid of 8 patients with arthropathy, and have led to the development of the lymphoid cell line IVPat-88. Cell line has been propagated by serial passages for more than 14 weeks in continuous culture. The cells grew as single, free-floating individuals, or in dense clumps without adherence to glass or plastic surface. All these cells were identified as altered lymphoblasts because of their growth pattern and uniform morphology, and the presence of Epstein-Barr Viral Capsid Antigen (VCA) in 5 to 10% of the cells. The cell concentration varied during the period of culture from about 300,000 to 1,700,000 cells per ml, and mean doubling time during phases of active growth was 42 and 60 hours in MEM and RPMI 1640 tissue culture media, respectively. The methods used and the characteristics of the cell line are described.     

The presence of complement fixing antibodies to Rous sarcoma virus (Schmidt-Ruppin strain) in patients with various forms of neoplasia.

The presence in men of antibodies to Rous sarcoma virus, an oncogenic virus of avian origin, was demonstrated. The highest antibody incidence was found in patients with various forms of cancer (34.4%, as against the value of 12% recorded in blood donors); these patients also showed an increased antibody level - 1/64 titers were detected in 43 out of 7 patients. The possibility of a human infection with animal oncogenic viruses is discussed, without excluding the hypothesis of a paraimmune reaction.     

Possible relation between viruses and oromaxillofacial tumors. V. Demonstration of hemagglutination-inhibiting anti-BK virus antibodies in patients with tumors of the parotid gland

Anti-BK-virus hemagglutination inhibiting antibodies were revealed in 81.8% of the patients with parotid gland tumors. Results of the investigations conducted on oromaxillofacial tumors including the parotid gland ones are discussed from the point of view of the presence of viral antigens (herpes-, SV40 and BK-viruses) and of specific antibodies. Possible implication of the papova viruses in the etiopathogenesis of the parotid gland tumors in humans are also discussed.     

Possible relation between viruses and oromaxillofacial tumors. III. Demonstration of the SV40 antigen and anti-SV40 antibodies in patients with tumors of the parotid gland

SV40 antigen was detected in 7 of 13 malignant tumors developed in the head and neck region. Specific complement fixing antibodies were found in all the patients with the SV40 antigen present in the parotid gland tumoral cells. Incidence of the anti-SV40 complement fixing antibodies in parotid gland tumor bearing patients was of 69.6%.     

IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome

BACKGROUND: A unique subset of patients with chronic fatigue syndrome (CFS) and IgM serum antibodies to cytomegalovirus (HCMV) non-structural gene products p52 and CM2 (UL 44 and UL 57) has been described. PATIENTS AND METHODS: Fifty-eight CFS patients and 68 non-CFS matched controls were studied. Serum antibodies to EBV viral capsid antigen (VCA) IgM and EBV Early Antigen, diffuse (EA, D) as well HVCMV(V), IgM and IgG; VP (sucrose, density purified V); p52 and CM2 IgM serum antibodies were assayed. RESULTS: Mean age of CFS patients was 44 years (75% women). Control patients were 9 years older (73% women). Serum EBV VCA IgM positive antibody titers were identified in 33 CFS patients (Group A subset EBV VCA IgM 62.3+/-8.3, neg. <20), but were not present in other CFS patients, (Group B subset EBV VCA IgM 6.8+/-0.7) controls (p<0.0001). EBV VCA IgM titers remained positive in CFS patients from Group A for 24-42 months. CONCLUSION: Serum antibody to EBV VCA IgM may be a specific diagnostic test for a second subset of CFS patients.     

Warts and wart virus antibodies in patients with systemic lupus erythematosus.

Warts were found in 25 out of 56 patients with definite or probable systemic lupus erythematosus (SLE) but in only 19 out of 160 control patients. Warts were particularly prevalent in elderly patients with SLE. The corticosteroid and antimalarial drugs used to treat SLE did not influence the frequency of warts. Wart-virus antibodies were found significantly less often in patients with SLE than in controls: antibodies were detected in 23 out of 51 patients and in 40 out of 54 controls. Ihe findings suggest that some deficiency in the immune mechanisms of patients with SLE predisposes them to develop warts. There was an inverse correlation among the patients with SLE between the occurrence of warts and rheumatoid factor activity. This suggests that rheumatoid factor may interfere with resistance to warts.     

Transformation of human colostrum lymphocytes with Epstein-Barr virus.

Lymphocytes from human colostrum were transformed with EB virus to obtain immunoglobulin secreting cells. Equal proportions of IgG, IgA and IgM were detected in wells containing transformed colostrum cells. Pretreatment of colostrum cells with BCGF prior to EB virus infection reduced the transformation slightly. We discussed the possibility of establishing cell lines that produced human monoclonal antibody using colostrum cells.     

贵州地区非免疫缺陷相关性B细胞淋巴瘤与EB病毒的关系

目的 探讨非免疫缺陷相关性B细胞淋巴瘤与EB病毒的关系。方法 采用原位杂交、免疫组织化学方法分别检测63例贵州地区非免疫缺陷相关性B细胞淋巴瘤中的EBER1／2、LMP－1蛋白。结果 63例B细胞淋巴瘤中,6例EBER1／2（＋）（9．5％）,其中有4／13例上呼吸道淋巴瘤（30．8％）;仅有1／63例（1．6％）LMP－1（＋）。结论 非免疫缺陷相关性B细胞淋巴瘤与EB病毒的相关性小,其致瘤作用的发挥可能与机体的免疫状态有关。     

Frequent double infection with Epstein-Barr virus and human herpesvirus-6 in patients with acute infectious mononucleosis.

Clinical infectious mononucleosis (IM) represents a benign self-limited form of lymphoproliferative disease which is usually caused by infection with Epstein-Barr virus (EBV). Microscopic characteristics of this lymphoproliferative disorder, however, are not ultimately specific for EBV infection, but can also be seen in infections with other lymphotropic viruses, especially of the herpesvirus family. Human herpesvirus-6 (HHV-6) infection can apparently be associated with a number of diseases also seen in EBV infection. Also, postinfectious chronic fatigue syndrome (PICFS) which may follow IM is in more than 60% of the cases accompanied by persistent active HHV-6 infection. We thus screened serologically 215 cases of acute IM for evidence for infection with EBV, HHV-6 and CMN. Patients were tentatively grouped into those having primary infection or reactivated (probably non-primary) infections. Cases were followed for two years to monitor changes in titers. Of all 215 cases, 211 (98.1%) were positive for EBV, 137 (63.7%) for primary infections, 21 (9.8%) for reactivated infection, and 53 (24.6%) for latent EBV. Thirty-three (15.3%) cases had primary HHV-6 infection, 63 (29.3%) active or reactivated HHV-6 infection, and 71 (33.9%) latent HHV-6. Double active EBV and HHV-6 infection, including primary and reactivated infections, amounted to 89 (39.5%) cases. Cytomegalovirus (CMV) antibody titers were found in 81 (37%) cases, 48 (22.3%) of which indicated latent infection and 33 (15.3%) active infection. Only two cases had evidence of active CMV infection alone, 1 cases of active CMV and HHV-6 infection. Serologic titers in 12 (5.6%) cases indicated combined active infection with CMV, EBV and HHV-6.(ABSTRACT TRUNCATED AT 250 WORDS)     

Studies on the presence of viral antibodies in patients with various forms of malignant neoplasia.

The study of viral antibodies in 6714 sera demonstrated that the level of antibodies to infectious viruses was the same in cancer patients as in controls. However, the patients with various forms of neoplasia showed a considerable percentage and high antibody levels to viruses with oncogenic potential for animals (adenovirus, SV40, Rous virus) or involved in human carcinogenesis (herpes virus).     

Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay

A real-time quantitative PCR was developed to assess antiviral activity of molecules against human herpesvirus 8 (HHV-8) and the Epstein-Barr virus (EBV). The antiviral activity of the reference molecules acyclovir, ganciclovir, cidofovir, adefovir and brivudin, as assessed by this methodology, proved very similar to the activity as determined by a DNA-DNA hybridisation method.     

对南京地区各型肝炎患者TTV感染情况的调查

目的 了解南京地区肝炎患者TTV的感染情况。方法 用巢式聚合酶链反应对390例各型肝炎患者进行TTVDNA检测。结果 TTV在154例非甲～庚型肝炎患者和236例甲～庚型肝炎患者中的阳性率分别为11.69％(18/154)和12.71％(30/236);48例TTV阳性者中9例有输注血制品史。结论 TTV感染可能与部分非甲～庚型肝炎有关,TTV感染可能存在输血外的其他传播途径。